+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Checkpoint Inhibitors"

From
Immuno-Oncology Clinical Trials Market Report 2023-2033 - Product Thumbnail Image

Immuno-Oncology Clinical Trials Market Report 2023-2033

  • Report
  • September 2023
  • 249 Pages
  • Global
From
From
From
From
From
Global Cancer Photodynamic Therapy Market & Clinical Trial Insight 2030 - Product Thumbnail Image

Global Cancer Photodynamic Therapy Market & Clinical Trial Insight 2030

  • Clinical Trials
  • July 2025
  • 220 Pages
  • Global
From
Pipeline of c-Met-Targeted Immunotherapies - Product Thumbnail Image

Pipeline of c-Met-Targeted Immunotherapies

  • Report
  • August 2026
  • Global
From
Cancer Immunotherapy - A Global Market Overview - Product Thumbnail Image

Cancer Immunotherapy - A Global Market Overview

  • Report
  • November 2024
  • 256 Pages
  • Global
From
From
From
From
From
Loading Indicator

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more